PartnershipAug 5, 2026, 08:41 AM
Splash Beverage Group Partners for CannEpil® Veterinary Drug Development
AI Summary
Splash Beverage Group, Inc. announced a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product. The partnership will focus on companion-animal oncology and chronic pain management, with a goal to achieve FDA Center for Veterinary Medicine approval. Splash will retain ownership of all resulting data, intellectual property, and commercialization rights, while Lupvindol will lead the scientific and regulatory efforts.
Key Highlights
- Splash Beverage Group partnered with Lupvindol Biosciences for CannEpil® veterinary drug development.
- Collaboration targets companion-animal oncology and chronic pain management.
- Program aims for FDA Center for Veterinary Medicine approval, starting with INAD process.
- Splash retains ownership of medical technology, study data, intellectual property, and commercialization rights.
- Lupvindol Biosciences will lead scientific, product development, and FDA regulatory activities.
- Splash will provide milestone-based funding and lead commercialization strategy and capital-markets activities.
- Lupvindol CEO, Dr. Hunter Land, has experience with FDA-approved cannabinoid medicines like Epidiolex®.
- Global veterinary pain-management market is projected to reach $3.8 billion by 2030.
Price Impact
More from SBEV